Arbutus Biopharma Corp
ABUS
Rank in Stocks
#9921
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company,... Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Share Price
$3.88
Last synced: 2026-11-11
Market Cap
$770.87M
Change (1 day)
1.57%
Change (1 year)
-19.83%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Arbutus Biopharma Corp (ABUS)
Category
Healthcare
Earnings for Arbutus Biopharma Corp (ABUS)
Earnings in Jun 2026 TTM: $153.05M
According to Arbutus Biopharma Corp's latest financial reports, its current earnings (TTM) are $153.05M. In 2025 the company earned $-33.50M, an increase over its 2024 earnings of $-69.92M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Arbutus Biopharma Corp from 2000 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $153.05M | -556.86% |
| 2025 | $-33.50M | -52.09% |
| 2024 | $-69.92M | -4.02% |
| 2023 | $-72.85M | 12.05% |
| 2022 | $-65.01M | -14.74% |
| 2021 | $-76.25M | 19.61% |
| 2020 | $-63.75M | -61.69% |
| 2019 | $-166.38M | 170.98% |
| 2018 | $-61.40M | -43.51% |
| 2017 | $-108.70M | -77.78% |
| 2016 | $-489.10M | 532.68% |
| 2015 | $-77.31M | 99.76% |
| 2014 | $-38.70M | 175.17% |
| 2013 | $-14.06M | -146.96% |
| 2012 | $29.95M | -403.89% |
| 2011 | $-9.85M | -21.29% |
| 2010 | $-12.52M | 32.04% |
| 2009 | $-9.48M | -19.08% |
| 2008 | $-11.72M | 353.74% |
| 2007 | $-2.58M | -114.29% |
| 2006 | $18.08M | -335.67% |
| 2005 | $-7.67M | -74.26% |
| 2004 | $-29.80M | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | -100.00% |
| 2001 | $-15.96M | 0.00% |
| 2000 | 0.00 | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $4.76B | 3,009.69% |
US
|
|
| $-2.73B | -1,883.03% |
US
|
|
| $-4.02B | -2,724.04% |
AU
|
|
| $2.83B | 1,746.29% |
BE
|
|
| $1.50B | 878.05% |
NL
|
Questions about Arbutus Biopharma Corp's net income
What is Arbutus Biopharma Corp's net income?
Arbutus Biopharma Corp's net income over the last twelve months is $153.05M, as of Jun 2026.
What was Arbutus Biopharma Corp's net income in 2025?
In 2025, Arbutus Biopharma Corp's net income was $-33.50M, compared with $-69.92M in 2024.
How has Arbutus Biopharma Corp's net income changed since 2020?
From 2020 to 2025, Arbutus Biopharma Corp's net income was highest in 2025 ($-33.50M) and lowest in 2021 ($-76.25M).
How does Arbutus Biopharma Corp's net income compare with similar companies?
Arbutus Biopharma Corp's net income ($153.05M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.